Mercer Global Advisors’s Cardiff Oncology CRDF Stock Holding History

Mercer Global Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.6K	Buy	+12,755	New	+$20.3K	﹤0.01%	3604
2023 Q1	–	Sell	-147,857	Closed	-$207K	–	1953
2022 Q4	$207K	Hold	147,857	–	–	﹤0.01%	1698
2022 Q3	$228K	Hold	147,857	–	–	﹤0.01%	1566
2022 Q2	$325K	Hold	147,857	–	–	﹤0.01%	1386
2022 Q1	$367K	Sell	147,857 -40,500	-22%	-$143K	﹤0.01%	1401
2021 Q4	$1.13M	Buy	188,357 +15,000	+9%	+$89.4K	0.01%	830
2021 Q3	$1.16M	Buy	173,357 +5,500	+3%	+$34.5K	0.01%	793
2021 Q2	$1.12M	Buy	167,857 +10,000	+6%	+$84.8K	0.01%	785
2021 Q1	$1.46M	Buy	157,857 +22,007	+16%	+$267K	0.01%	642
2020 Q4	$2.44M	Hold	135,850	–	–	0.03%	374
2020 Q3	$1.93M	Buy	135,850 +200	+0.1%	+$1.32K	0.03%	392
2020 Q2	$680K	Buy	+135,650	New	+$278K	0.01%	580

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Mercer Global Advisors's CRDF Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Cardiff Oncology (CRDF) in Q2 2026: 12,755 shares worth $16.6K. The stake represents ﹤0.01% of the portfolio and ranks #3604 among its holdings. This is a return to the name: Mercer Global Advisors previously reported a position in CRDF as recently as Q4 2022.

Mercer Global Advisors first reported a position in CRDF in Q2 2020 and has held it in 12 quarters since. The position peaked at $2.44M in Q4 2020. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

Mercer Global Advisors held 12,755 shares of Cardiff Oncology worth $16.6K as of Q2 2026.
Cardiff Oncology was a new Mercer Global Advisors position in Q2 2026.
Cardiff Oncology made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3604 holding.
Mercer Global Advisors first reported a position in Cardiff Oncology in Q2 2020 and has held it in 12 quarters since.
Mercer Global Advisors's Cardiff Oncology position peaked at $2.44M in Q4 2020.
105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.